|
Post by lakers on Oct 17, 2017 18:14:11 GMT -5
OUTSULIN Trade mark is active in Australia, Mexico, pending in Canada, U.S. With a new label, could there be partners in Australia, Mexico, Canada? www.wipo.int/branddb/en/search for OUTSULIN 1735286 - OUTSULIN Status: Active (2017-03-22)
(111) Registration Number 1735286 (151) Date of the registration 2017-03-22 (210) Serial number of the application 0119851820281 (220) Date of filing of the application 2016-11-11 (731) Name and address of the applicant MANNKIND CORPORATION RYE CANYON LOOP NUM. EXT. 25134 NUM. INT. SUITE 300 VALENCIA, CA., ESTADOS UNIDOS DE AMERICA (91355) (740) Name and address of the representativeANTONIO BELAUNZARAN MARTINEZ
PEDRO LUIS OGAZON NUM. EXT. 17, SAN ANGEL
ALVARO OBREGON, CIUDAD DE MEXICO (01000)
(511) The International Classification of Goods and Services for the Purposes of the Registration of Marks (Nice Classification) and the list of goods and services classified according thereto 5PRODUCTOS FARMACEUTICOS, A SABER, PREPARACIONES FARMACEUTICAS PARA EL TRATAMIENTO DE LA DIABETES, ENFERMEDADES Y DESORDENES ENDOCRINOS, ENFERMEDADES Y DESORDENES METABOLICOS; PREPARACIONES FARMACEUTICAS QUE CONTIENES INSULINA. 1808539 - OUTSULIN Status: Registered/Protected(151) Date of the registration 2016-11-10 (731) Name and address of the applicant MannKind Corporation a Delaware corporation 25134 Rye Canyon Loop Suite 300 Valencia CA 91355 US (750) Address for correspondence
Davies Collison Cave Pty Ltd
Level 15
1 Nicholson Street
MELBOURNE
VIC
3000
AU
(511) The International Classification of Goods and Services for the Purposes of the Registration of Marks (Nice Classification) and the list of goods and services classified according thereto 5 Pharmaceutical products, namely, pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders; pharmaceutical preparations containing insulin44 Medical information App.1810093 - OUTSULIN Status: Trade-mark: Advertised(210) Serial number of the application 1810093 (220) Date of filing of the application 2016-11-18 (527) Indications regarding use requirements Proposed Use in CANADA
(300) Data relating to priority under the Paris Convention and other data relating to registration of the mark in the country of origin Priority Filing Date: May 18, 2016, Country: UNITED STATES OF AMERICA, Application No. 87042197 in association with the same kind of goods and in association with the same kind of services (550) Indication relating to the nature or kind of mark Trade-mark (Word Mark) (731) Name and address of the applicant MannKind Corporation 25134 Rye Canyon Loop Suite 300 Valencia, CA 91355 US (740) Name and address of the representative
GOWLING WLG (CANADA) LLP
SUITE 1600
1 FIRST CANADIAN PLACE
100 KING STREET WEST
TORONTO
ONTARIO
M5X1G5
CA510) List of goods and/or services, if not classified (1) Pharmaceutical products, namely, pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders; pharmaceutical preparations containing insulin (1) Medical information
|
|
|
Post by lakers on Oct 17, 2017 11:25:56 GMT -5
|
|
|
Post by lakers on Oct 15, 2017 2:37:01 GMT -5
Afrezza News: Could New Labeling Change the Game? Written by Mike Hoskins and Amy Tenderich Published on October 10, 2017 www.healthline.com/diabetesmine/afrezza-inhaled-insulin-new-labelingExcerpts follow. The Future for Afrezza (?) With recent news of Novo's Fiasp approval helping MannKind compare the fast action of both insulins, and with both Dexcom CGM and the newly-approved Abbott FreeStyle Libre allowing more real-time data comparison, Castagna sees this as an especially exciting time for this Afrezza label change to happen. "It's important for us," he says. "While it may seem simple on the surface, I would highlight that just being able to understand what a 4-unit cartridge does... is key. It's the first time a doctor will be able to really see and understand, and that's really important when you think of your child or loved one going to bed, and not seeing nocturnal hypoglycemia or sugars running high. To be able to know your sugars will comfortably come down over a certain period of time is really important. We think that's critical as we go forward." Aside from these label changes, MannKind says it also recently dosed its first pediatric patient in the clinical trials setting (in collaboration with JDRF), and is exploring a 2-unit cartridge as a possibility for kids down the road. The company also just filed for regulatory approval in Brazil, as the first international country to start selling this inhaled insulin globally. Importantly, MannKind also said it's continuing conversations with payers for increased access, and the company expects this label change to help motivate more payers to put Afrezza on the formulary for patients. Improved access will be a crucial step in all of this, Castagna says. We're happy to hear of this progress for MannKind, and hope for the best on everything related to Afrezza. This product works well for us (both 'Mine editor AmyT and I myself use it), and we certainly continue keeping our fingers crossed that Afrezza becomes an option for anyone who wants it. Whether this label change is really the trigger remains to be seen.
|
|
|
Post by lakers on Oct 14, 2017 19:02:27 GMT -5
This article is almost two years old. I think Cipla might be the largest biopharma in the world. I wonder if they dropped the attempt with their own inhalable insulin. Talking about Cipla, Upadhye said, “We have a very strong presence in South Africa’s private as well as tender market. Cipla is the 4th largest company in the private pharma market and 3rd overall, including tender business. United States is also our priority market and our focus will be to grow our US franchise disproportionately.” health.economictimes.indiatimes.com/news/pharma/the-state-of-pharmaceutical-industry-in-india-an-overview/60273583Key players in the global dry powder inhalers market are Orion, Novartis, MicroDose Therapeutx, Meda, Mannkind, Mantecorp, Hovione, GlaxoSmithKline, Civitas/Alkermes, Cipla, Chiesi, Boehringer Ingelheim, AstraZeneca, and Aerovance, among others. www.lanews.org/dry-powder-inhalers-market-industrial-forecast-on-global-industry-analysis-and-trends-till-2025/
|
|
|
Post by lakers on Oct 14, 2017 12:00:14 GMT -5
|
|
|
Post by lakers on Oct 14, 2017 11:34:34 GMT -5
|
|
|
Post by lakers on Oct 13, 2017 18:48:55 GMT -5
|
|
|
Post by lakers on Oct 13, 2017 18:07:40 GMT -5
Schedule 13D is an SEC filing that must be submitted to the US Securities and Exchange Commission within 10 days by anyone who acquires beneficial ownership of more than 5% of any class of publicly traded securities in a public company.
In the next 2 weeks,we will learn the identity of the new 10M share owner. Could it be the backers of RLS? Hello Paul and Jeff! If it is you, MNkd 's future is bright!
|
|
|
Post by lakers on Oct 13, 2017 17:35:34 GMT -5
Biomm SA, formerly Savicevic Participacoes SA, is a Brazil-based company primarily engaged in the biotechnology industry. The Company is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Company’s technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Company’s technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Company’s subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.
A Precursor to partnering in UAE, Saudi Arabia, Oman, B, R of BRIC ? Afrezza was trademarked in Russia in 2015, the same year as Mexico, Canada.
|
|
|
Post by lakers on Oct 13, 2017 16:36:34 GMT -5
The CoB bought 1,666,600 @ $6 ~ $10M not 1M. This should propel the stock back to $6 and more. He must have known something.
|
|
|
Post by lakers on Oct 12, 2017 0:45:12 GMT -5
New Label For Afrezza Could Turn Things Around At MannKind m.benzinga.com/article/10160000?utm_referrer=https%3A%2F%2Fwww.google.com%2FDespite a more than 200-percent gain in MannKind Corporation (NASDAQ: MNKD)'s stock over the past month alone analysts at H.C. Wainwright see even further upside ahead. The firm's Oren Livnat initiates coverage of MannKind's stock with a Buy rating and $7 price target, which represents a gain of more than $1 per share from Tuesday's opening price of $5.89 (see Livnat's track record here). After spending more than $2 billion over two decades developing the only approved inhaled and rapid-acting insulin therapy for diabetes called Afrezza, MannKind went on to secure a "blockbuster" partnership with Sanofi SA (ADR) (NYSE: SNY). However, since then a "disappointing partner launch" resulted in Afrezza being returned in 2016 and the stock plummeted 98 percent from peak to trough. Meanwhile, Wall Street "largely wrote off" Afrezza and MannKind's stock but this perception could change under a new management team and a "game-changing" new label, which was approved last week, the analyst continued. Specifically, Afrezza could gain traction in the "very large" insulin space and prove to be the "significant product that its innovation merits." "We believe Afrezza inhaled insulin is a clearly differentiated meal-time insulin therapy vs. injectable market leaders Novolog and Humalog, which combine for $3.5B in the U.S.," the analyst explained. "Besides the apparent advantages of a more convenient and less stigmatizing puff on an inhaler at meal-time vs. injections, the even greater value of Afrezza is its inherent "faster in, faster out" pharmacodynamics (PD), which more closely mimic endogenous insulin in healthy people. Faster in and out means that it should better control glucose at meal-time and lower risk of delayed hypoglycemia, which is the biggest risk of insulin therapy." Bottom line, MannKind will evolve from being "knocked out to take out" by a larger player as the company accelerates Afrezza's growth and achieve peak sales of more than $725 million in the U.S. At time of publication, shares of MannKind were up 26.08 percent at $6.72.
|
|
|
Post by lakers on Oct 11, 2017 16:26:56 GMT -5
10% dilution, 18.48% Pps drop, overdone, shorts piled in. After this Week, Pps might float back to $6. Mnkd can now negotiate in a better position of strength. Next on deck are ER, international expansions, STAT completion 10/15/17.
|
|
|
Post by lakers on Oct 11, 2017 13:05:15 GMT -5
|
|
|
Post by lakers on Oct 10, 2017 15:51:19 GMT -5
|
|
|
Post by lakers on Oct 9, 2017 3:10:34 GMT -5
Aged, the followings should light your bulb. We’ve got the next generation already on the drawing board. They’re very excited to team with the DreaMed group, with their fuzzy logic. So, the next generation algorithm will be, if you’d like it to be, a little bit more aggressive. So, we are excited about that, more automatic bolusing so that the patient is going to be asked to do less and less, and the device will do more and more. We are looking at the use with ultra-rapid-acting insulin to see how far that gets us down the line of not having to inform about an upcoming meal. So very excited about that pathway. we just released in Europe, hopefully in the U.S. pretty soon – a stand-alone sensor and straight to the cell phone. Along with it you’ll be able to get an app that we’ve been collaborating with IBM to have advanced analytics, really big data learning, machine learning, so that patients can start to understand their patterns and trends; see where there might be a problem with their overall management, including a big nutritional component if that’s what they’d like. Read more: mnkd.proboards.com/thread/8688/kaufman-medtronic-ultra-rapid-insulin#ixzz4uBFJh36UIn addition, Castagna said the FDA approved a glucose monitoring system that could spur sales to Type 2 diabetes customers. He said current MannKind sales are evenly split between Type 1 and Type 2 diabetes patients, although 95 percent of overall diabetes patients have Type 2. Being able to check your blood sugar without pricking your finger six or seven times a day will make it easier for people to figure out how to manage their glucose control,” he said. Read more: mnkd.proboards.com/thread/8790/danbury-times#ixzz4uzqLNl7n
|
|